Back to search

Article

Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational Study

2023-05-10

Abstract excerpt

Background: Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are scarce and inconclusive. In particular, no adequately powered studies have demonstrated statistically significant differences in mortality between the two oral antivirals. We therefore aimed to provide a comparison of all-cause mortality in community-dwelling COVID-19 patients treated du...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
39422ae9-8c4c-5d0c-8158-9b1a97258bac
DOI
10.2139/ssrn.4444431
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-Life Comparison of Mortality in Non-Hospitalised Patients with SARS-CoV-2 Infection at Risk for Clinical Progression Treated with Molnupiravir or Nirmatrevir Plus Ritonavir During the Omicron Era in Italy: A Nationwide, Observational StudyDOI 10.2139/ssrn.4444431
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity
Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)Semantic proximity
Association of Molnupiravir and Nirmatrelvir-Ritonavir with Reduced Mortality and All-cause Sepsis in Hospitalized Patients Infected with Omicron Variant of SARS-CoV-2: A Territory-Wide Prospective Cohort StudySemantic proximity
Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity
Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha RegistrySemantic proximity
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational studySemantic proximity
Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity
Effectiveness of Molnupiravir for the Treatment of COVID-19: A Systematic Literature Review of Real-World Observational StudiesSemantic proximity
REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADASemantic proximity
Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2: A single-center large observational studySemantic proximity
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir among COVID-19 community, highly vaccinated patients with high risk for severe disease: Evidence that both antivirals reduce the risk for disease progression and deathSemantic proximity
Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity
Select a neighboring publication to make it the new centre.